Chief Executive Officer & Portfolio Manager
Joseph founded Perceptive Advisors, LLC in 1999. Previously, he was Senior Analyst at Aries Fund, a Paramount Capital Asset Management biotechnology hedge fund, from November 1994 through December 1998. Prior, he was Senior Biotechnology Analyst at Prudential Securities for four years. He started his career in the healthcare sector of the securities industry as Biotechnology Analyst at Labe, Simpson. Joseph earned an M.B.A. from New York University and a B.A., magna cum laude, in psychology from the University of California San Diego.
Chief Investment Officer
In 2006 Adam Stone joined Perceptive. Prior to Perceptive he was a senior analyst at Ursus Capital. During his five years there he focused on biotech and specialty pharmaceuticals. He graduated, with honors, from Princeton University with a B.A. in molecular biology. Adam serves on the board of directors for several of Perceptive’s portfolio companies, including Solid Biosciences, Renovia, and Xontogeny. He is also a member of Perceptive’s internal investment committees for the credit opportunities and venture funds.
Portfolio Manager, Credit
Sam Chawla brings over 15 years of experience in healthcare corporate finance to Perceptive. Prior to joining in 2013, he was Managing Director in the Global Healthcare Group at UBS Investment Bank. Sam has in-depth experience in M&A advisory, underwriting debt and equity financings across healthcare. He graduated from Johns Hopkins University with a B.A. in Economics and from Georgetown University with a MBA.
Michael Altman, CFA
Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team. His focus is on medical devices, diagnostics, digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvius Therapeutics.
Hossein Ekrami, PH.D.
Hossein Ekrami joined Perceptive in 2007 from healthcare hedge fund Ursus Capital, where he was a Senior Analyst focused on specialty pharmaceuticals, generics, and biotech for more than seven years. Hossein earned his Ph.D. at the University of Southern California and his undergraduate degree, with honors, from London University.
Ellen Hukkelhoven, PH.D.
Ellen Hukkelhoven joined Perceptive in 2013 as a Senior Biotechnology Analyst. At Perceptive, she focuses on therapeutics, genetic diseases, and cancer biology, working primarily on investments with development-stage therapeutics companies. Ellen serves on the board of MeiraGTx. Prior to Perceptive, Ellen received her PhD in Cancer Biology from Memorial Sloan Kettering Cancer Center. During her tenure at MSKCC, she founded and built the life sciences division of InSITE, a top graduate fellowship program that helps early stage companies with their most pressing needs. Ellen graduated magna cum laude from Princeton University with degrees in molecular biology and finance.
Craig Yeshion, MD
Craig Yeshion joined Perceptive in 2016. Prior to joining the firm he was a Portfolio Manager for J. Goldman & Co. covering medical devices and diagnostics from 2012 through 2016. Prior to J. Goldman, he spent 5 years covering medical devices, and biotechnology as a Senior Analyst for Accipiter Capital Management, and 6 years as an analyst for Ursus Capital. Craig received his Medical degree with Honors from the Cornell University Medical College in 1995. He completed his Internal Medicine residency at New York Hospital Cornell Medical Center, and was a physician in private practice from 1995-2000. He received a B.A. in Economics from the University of Pennsylvania.
Weston Nichols, PH.D.
Weston Nichols joined Perceptive in 2016 from Balyasny Asset Management where he was a biotech analyst. He earned his Ph.D. in neuroscience from Caltech, and undergraduate degree in biological engineering from Cornell.
Keyvan Mirsaeedi-Farahani, MD
Keyvan Mirsaeedi-Farahani joined Perceptive in 2016 after earning an MD from the University of Pennsylvania and an MBA from the Harvard Business School. He previously spent two years as an analyst with McKinsey. Keyvan graduated Phi Beta Kappa from the University of Michigan with a BS in molecular biology as well as an undergraduate business degree.
Greg Raffo joined Perceptive in February, 2010 from Grace Financial Group, a brokerage firm, where he was a sales trader covering the healthcare space. Prior to that he was an equity research analyst for Boenning & Scattergood, Inc. where he covered financial companies. Greg graduated from Wake Forest University in 2003 with a BS in Business.
Chief Credit Officer
Sandeep Dixit brings 15 years of experience to Perceptive. He was formerly Managing Director, Fort Hill Investment Partners and a Vice President at Fortress Investment Group, Drawbridge Special Opportunities Fund. Sandeep has an extensive credit structuring, underwriting and portfolio management background encompassing direct lending, leveraged loans and high yield bonds. He graduated cum laude with a B.S. in Economics from The Wharton School, University of Pennsylvania.
Portfolio Manager – Venture
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept, and formed a partnership with Perceptive in 2017 to establish the firm’s venture fund strategy. As a member of the Perceptive Investment Team, Chris will help source and identify venture opportunities for investment as part of the Xontogeny portfolio and beyond. Chris has a broad base of experience and a track record of success across his 25 years in the pharma and biotech industries, including at two of the most successful biopharma companies over the last 20 years, Gilead and Celgene. Most recently, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris served as VP of Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global leadership roles at Gilead from 1997 to 2005, including as VP of Corporate Development, VP of Medical Affairs and VP of Marketing. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group.
Corporate Development – Venture
Fred Callori joined Xontogeny in September 2017 to support the company’s strategic and operational objectives, including providing overall corporate governance, transactional, and strategic advice to Xontogeny’s portfolio of companies. Fred also joined Perceptive in September 2017 to support the firm’s venture fund strategy. As a member of the Perceptive Investment Team, Fred will help source and evaluate venture opportunities for investment as part of the Xontogeny portfolio and beyond. Fred developed deep experience working with early stage life science companies as a partner in the Life Science and Emerging Companies practices of Choate, Hall & Stewart LLP, a Boston law firm ranked among the most active firms worldwide for private equity and venture capital deals. During his 20 year tenure at Choate, Fred advised clients on the formation, structure, financing and overall corporate development of early stage and emerging life science companies, including representing leading venture capital and institutional investment firms focused on investing in the sector. Fred holds a JD from Boston University School of Law and a BA in Economics from Binghamton University.